Latest Commercialisation News

ImpediMed secures expanded insurance reimbursement for its SOZO platform, now covering over 301 million US lives and enhancing early detection of breast cancer-related lymphedema.

Intelligent Monitoring Group has acquired BNP Securities for $4.2 million, aiming to blend traditional security manpower with advanced video monitoring solutions. This move is set to boost earnings and broaden ADT Guard’s presence in Australia’s security market.

Podium Minerals has announced a major metallurgical breakthrough with a new concentrator flowsheet achieving approximately 80% recovery of key platinum group metals, advancing its Parks Reef Project towards commercialisation.

CONNEQT Health has raised $2 million through a convertible note facility with a director-owned entity, providing fresh capital to support its growth plans. Shareholder approval will be key to unlocking the full benefits of this funding.

G50 Corp has completed the acquisition of 100% ownership of its Golconda Project in Arizona, following significant exploration successes that position the company for accelerated development and commercialisation.

Memphasys Limited has revised its FY25 financials to reflect a $1.12 million liability linked to uncertain compliance with R&D tax incentive rules, pending a private tax ruling.

FBR Limited’s 2025 Annual Report reveals a substantial $54 million impairment charge that significantly worsens its financial results, pushing total losses to nearly $83 million. The adjustments highlight challenges in capitalised development and asset valuations amid ongoing robotics innovation.

PARKD Limited has completed the first tranche of its $0.78 million placement, issuing over 20 million shares at 3 cents each, while launching a Share Purchase Plan for existing shareholders.

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

Dotz Nano has secured its first commercial order for its innovative Amine-Modified Polymer CO2 sorbent from a leading automotive innovation hub, marking a key step toward commercial deployment in sustainable aviation fuel production.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Orthocell has appointed its first Canadian distributor for Remplir, its innovative nerve repair device, ahead of an official launch at a major surgical conference in Vancouver. The move marks a significant step in expanding the product’s international footprint.